Drug Trial Radar · NCT07609719
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Feb 28, 2029
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).
Conditions
- Multiple Sclerosis
Interventions
OCR SCDrug
Participants will receive OCR SC as per the schedule specified in the arm and the United States Prescribing Information (USPI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With no Change or Reduction From Baseline in Number of T1 Gadolinium-enhanced (Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Week 24Time frame: Baseline, Week 24
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates
Birmingham, Alabama · Recruiting
Clinical Endpoints, LLC
Scottsdale, Arizona · Recruiting
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado · Recruiting
Neurology Associates, PA
Maitland, Florida · Recruiting
Atlanta Neuroscience Institute
Atlanta, Georgia · Recruiting
Savannah Neurology Specialists,PC
Savannah, Georgia · Recruiting
Neurology Clinic PC
Cordova, Tennessee · Recruiting
Caribbean Center for Clinical Research
Guaynabo, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.